Janux Therapeutics Inc. (NASDAQ:JANX) is one of the best up and coming stocks with huge upside potential. On September 10, Truist initiated coverage of Janux Therapeutics with a Buy rating and $100 price target. Truist believes that the company’s masking platform has the potential to overcome the limitations of T-cell engagers in solid tumors by improving safety and efficacy through tumor-activated masking. For Q2 2025, Janux reported a net loss of $33.9 million, which is an increase from the $6.0 million ...